TAG advocates for responsible public policy on AIDS research and treatment with our nation's leaders, including members of Congress and officials from the relevant agencies in the Executive Branch. We push for more funding for AIDS research and sensible legislative initiatives to foster better biomedical research. TAG also advocates for sound regulatory policy in the evaluation of AIDS drugs which balances the need for access to new agents and the need for reliable information about their clinical efficacy.

Activism Links & Resources

Links to activist websites

Activism & Policy : Current

• Moving from Universal Access to Comprehensive and Universal Primary Health Care for All
  powerpoint | word
  Looking to the Future—the Epidemic in 2031 and New Directions in AIDS Research • plenary session • Mark Harrington, Executive Director, TAG • XVII International AIDS Conference, Mexico City, Mexico, 6 August 2008
• Open letter from the Fair Pricing Coalition re pricing of Merck's Isentress®
• Sign-on letter protesting death of Victoria Arellano
  In detention at San Pedro, Victoria Arellan was denied AIDS medications. (added 9/14/2007)
• Open letter re firing of South African Deputy Health Minister
  Advocates' letter to President Mbeki regarding the firing of South African Deputy Health Minister Nozizwe Madlala-Routledge. (added 8/31/2007)
• Advocates' Letter to Congress Supporting Microbicide Development Act (added 2/23/2007)
• Advocates' Open Letter to WHO
  regarding compulsory licensing and the Thai government
• Sign-on letter to Congress raises questions about NIH Reauthorization bill (added 12/8/2006)
• Sign-on letter to HHS in support of global funding for HIV/AIDS
• Executive Director's Statement on Life & Legacy of Dr. Lee Jong-Wook, Director, World Health Organization (WHO)
• Sign-on letter to WHO to Keep 3 X 5 Alive
  by The International Treatment Preparedness Coalition to Director General.
• Sign-on letter to Abbott Laboratories re unavailability of Kaletra
• Sign-on letter to WHO re rescheduling of buprenorphine
  International sign-on letter to Director General of World Health Organzation on the thirty-fourth Expert Committee On Drug Dependence (ECDD) meeting in Geneva on 28-31 March and "final decision" regarding rescheduling of buprenorphine.

Activism & Policy : 2005

• Continuing the nation's investment in medical research
  sign-on letter re funding for the National Institutes of Health
• ITPC Involvement of UNAIDS in the Response to HIV/TB
  email to Peter Piot
• Making Methadone Accessible–Beyond the Listing in the WHO EDL
  sign-on letter to WHO and UN program leaders
• Save ADAP August campaign – includes sample letter to President
• Letter to House on draft NIH Reauthorization Legislation
  requesting Congress to preserve the powers of the Office of AIDS Research
• Sign-on letter condemns violence against proteststers in Queenstown, SA
• AIDS Activists Cry Foul as Drug Companies Push Prices to Record Levels
• Open letter to Ambassador Tobias regarding the efficacy of needle exchange
• Mandatory 'Anti-Prostitution Pledge' Threatens Lives of Sex Workers and Trafficking Victims
  Press release from the Center for Health & Gender Equity
• Global Policies Undermined by Restrictions to Healthcare Appropriations
  sign-on protest letter to President Bush
• Sign-on letters addressing funding for HCV
  to the Senate Appropriations Subcommittee on Labor and the House Appropriations Subcommittee on Labor
• The Need to Coordinate and Clarify Efforts
  Letter to UNAIDS director regarding needed coordination of efforts between WHO and UNAIDS, with his reply.
• Support the Santorum-Durbin Amendment to Budget
  for Global Fund to Fight AIDS, Tuberculosis, and Malaria
• Thai-US CDC Tenofovir Prevention Trial
  Ignores International Ethical Standards and Exploits Injecting Drug Users in Thailand
• AIDS Community Statement: NY Case of Rapidly Progressing Multi-Drug Resistant HIV Infection
  open sign-on letter includes backgrounder.
• U.S. Gag on Needle Exchange Harms U.N. AIDS Efforts

Activism & Policy : 2004

• Mientras España duerme
  La Conferencia Internacional de SIDA, Bangkok, 11-16 de Julio, 2004 (added 12/28/2004)
• FDA letter re CDER meeting and need for post approval pharmacokinetic and drug-drug studies (added 12/28/2004)
• Thai Activists Speak Out on Tenofovir Trial in IDUs (added 12/8/2004)
• Community letter protests proposed NIH grant cycle
• People with HIV/AIDS From Around the World Condemn Bush Administration's Attacks on the Global Fund to Fight AIDS, Tuberculosis and Malaria and the World Health Organization
• Activists Demand Permanent Price Freeze on AIDS and Hepatitis C Medications
  —200 groups send letter to CEOs of 7 companies
• Sign-on letter protesting Thai drug policies
  The impact of Thaksin's drug policy on Thailand's HIV/AIDS epidemic (added 10/12/2004)
  
• Response from Peter Piot: Re Drug Pricing for Middle Income Countries letter
• Operational Research Standoff in Bangkok (added 8/27/2004)
  Bangkok e-confrontation on NIH failure to commit adequate resources and leadership to effectiveness research relevant to AIDS program scale-up in developing countries
• Letter to the International Monetary Fund and the World Bank (added 8/14/2004)
  Support the Millennium Development Goals: reverse the spread of AIDS, tuberculosis, and malaria by 2015 • reduce the child mortality rate in 2015 by two-thirds compared to 1990 • reduce the maternal mortality in 2015 by three-quarters compared to 1990.
• Call to Action from Thai AIDS Treatment Activists (added 6/28/2004)
  AIDS 2004—XV International AIDS Conference: Thai AIDS Treatment Activists Invite Allies to Join a March and Protest to Demand Accountability and Action on AIDS
• FDA letter: Disclosing Risk Information in Consumer-Directed Print Advertisements (added 5/18/2004)
• Sign-on letter: HHS blocks significant participation at Bangkok (added 4/30/2004)
• Sign-On letter re: Federal Budget Resolution
• World CAB (Community Advisory Board) Report: Focus on International Drg Pricing San Francisco February 5-7, 2004
• UN Letter on Price Reductions for low- to middle-income countries • August reply to letter

Activism Archives : 2003 & earlier

• White House blocks use of affordable medicines - sign-on protest letter
• AIDS Activists Blast Roche's 'Pay or Die' Policy
• TAG expresses concern over weak scientific basis for first NIH-sposored AIDS vaccine efficacy trial
• STOP AIDS Consensus Statement, 2003
• Letter to FDA re: proposed new federal regulations
• Medicare is an AIDS Issue Letter
• FDA letter re Trizivir
• Sign-on letter protesting redirection of funds away from the NIAID
• Sign-on letter supporting lower drug prices for non-OECD countries (added 7/1/2003)
• Sign-on letter to the President re Domestic AIDS Policies
• Retrovirus 2003 Conference – Developing World Report
• Sign-on letter supporting lower drug prices for ADAP
• HIV Community Concerns Regarding Need for Additional Studies for Full Approval of Atazanavir - letter to FDA
• Fair Pricing Coalition to Industry: 2 sign-on letters
  The ADAP Crisis · The Cost of Drugs
• Senate Global AIDS Bill Sign-on Letter
• Fuzeon brand enfuvirtide (T-20) – Breaking barriers or breaking the bank?
  Position paper by Matt Sharp and Rob Camp
• AIDSVAX Fails to Protect; VaxGen's Claims of Efficacy in Black and Asian Participants are Misleading and Premature
• Federal AIDS Policy Meeting Notes
• Consensus Statement on Roche Pricing of Pegasys for Treatment of HCV Infection | Addendum/background to Roche Pricing Letter
• Working Meeting on an International Action Plan on Scaling Up Access to HIV Care
  Geneva · October 2002
• Comment on IAP meeting Richard Stern, Director, Agua Buena Human Rights Association
• Consensus Statement in Opposition to Licensure of Remune as Monotherapy for HIV Infection in Thailand
• Comments on Problems in the First Draft World Health Organization (WHO) Antiretroviral Treatment Guidelines for Resource Limited Settings
• Email responses to the above article
• To Double, or Not to Double? Bioterror Buys a Budget Boost
• Press release on tenefovir NDA
• Position Paper on NDA 21-356 for Gilead Sciences' Viread™ brand Tenofovir disoproxil fumarate
• The Role of Community Advisory Boards (CABs) in Resolving Ethical Issues
  Solid Organ Transplantation and People with HIV
  Ethics & Policy Conference - Washington, D.C. 28 July 2001
  the powerpoint slides from Michael Marco's plenary session presentation

  "We Don't Need Another Venue" -- Meeting on Global Treatment Access, or Industry Sideshow?

  Meeting with Merck April 20, 2001

  Meeting at the U.S. Trade Representative's Office on U.S. Trade Policy on Drugs for HIV/AIDS

  Brazil: What Went Right? The Global Challenge of Access to Treatment & the Issue of Compulsory Licensing

  Press Release announcement of report, Exploring the American Response to the Global AIDS Pandemic

  Exploring the American Response to the Global AIDS Pandemic—also in PDF format

  A Statement by Gregg Gonsalves, Policy Director of the Treatment Action Group, on the Vaccines for the New Millennium Act of 2000

  The Question of Gene Patents

  Policy Statement on NDA 20-993, Gilead Sciences, Inc's Application for Approval of Preveon™

  Policy Report on Application for Agenerase^™ Approval

  Notes from the Gallo Lab Meeting